Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

114.23 +3.73 (+3.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
It's always tough to be compared to a giant. 
Via The Motley Fool
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. 
Via MarketBeat
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
One pundit feels there is solid potential in one of the company's more recently approved drugs. 
Via The Motley Fool
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. 
Via InvestorPlace
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
From Sarepta Therapeutics, Inc.
Via Business Wire
A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?
Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product  
Via Benzinga
Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match
Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match. 
Via InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram. 
Via InvestorPlace
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
Can this struggling stock turn its fortunes around? 
Via The Motley Fool
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
Last year wasn't great for either stock, but that's no reason to ignore them. 
Via The Motley Fool
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
From Sarepta Therapeutics, Inc.
Via Business Wire
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech... 
Via Talk Markets
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
3 Things About Sarepta Therapeutics Every Smart Investor Knows
Mastering this stock requires appreciating a few scientific nuances. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Both develop medicines for rare diseases, and each aims to conquer a niche market. 
Via The Motley Fool
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
From Sarepta Therapeutics, Inc.
Via Business Wire
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
Many investors are bailing out, but that might be a mistake. 
Via The Motley Fool
My Take: 4 Strong Growth Stocks to Buy This Week
These strong stocks are still available at a great price. That may not be the case a whole lot longer. 
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.